Does Medi-Cal still cover Ozempic?

Yes, but only for type 2 diabetes — not for weight loss. While Ozempic frequently produces weight loss as a benefit, it cannot be prescribed through Medi-Cal solely for weight management. A type 2 diabetes diagnosis must be documented.

Why did Medi-Cal drop GLP-1 weight loss coverage?

The decision was driven by budget constraints, not a change in medical evidence. Covering weight loss GLP-1s for all eligible Medi-Cal enrollees was projected to add billions to annual spending, and DHCS needed to control costs amid federal Medicaid funding pressures.

What is the cheapest GLP-1 option for Medi-Cal patients who lost coverage?

Current options include orforglipron at approximately $149/month (oral pill), generic liraglutide at approximately $230/month, and Zepbound through LillyDirect at $299/month. Manufacturer patient assistance programs may also help qualifying patients.

Insurance & Cost

Medi-Cal GLP-1 Coverage in 2026: What's Covered, What's Not, and Your Options

Q: Can I appeal a Medi-Cal denial for a GLP-1 weight loss medication?

Yes. File a plan-level appeal within 60 days of denial, then request a State Fair Hearing if denied again. However, if the denial is based on the formulary exclusion without additional qualifying diagnoses, appeals are unlikely to succeed.

Sarah ChenLead Health Editor

Reviewed by Dr. James Okafor, PharmDPharmD

Updated March 29, 2026

Fact Checked

Medi-Cal stopped covering Wegovy, Zepbound, and Saxenda for weight loss in 2026. Learn what's still covered, your alternatives, and how to access GLP-1 medications in California.

Key Takeaways

Medi-Cal removed Wegovy, Zepbound, and Saxenda from its formulary for weight loss on January 1, 2026.
Ozempic, Mounjaro, and Rybelsus remain covered by Medi-Cal for type 2 diabetes at a $0–$3.80 copay.
Zepbound is available through LillyDirect at $299/month for patients without coverage.
Generic liraglutide (Teva's Saxenda generic) costs approximately $230/month as a cash-pay alternative.
Medi-Cal plan-level appeals must be filed within 60 days; state fair hearings are available at no cost.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

Medi-Cal GLP-1 Coverage in 2026: What's Covered, What's Not, and Your Options

If you're one of California's 15 million Medi-Cal enrollees searching for GLP-1 weight loss medication coverage, you need to know about a major policy change that took effect on January 1, 2026. The California Department of Health Care Services (DHCS) removed Wegovy, Zepbound, and Saxenda from the Medi-Cal formulary for weight loss indication — meaning these medications are no longer covered when prescribed specifically for obesity or weight management.

This is a significant blow for patients who relied on Medi-Cal to access these medications. But it's not the end of the road. GLP-1 medications prescribed for type 2 diabetes remain covered, and several alternative pathways exist for patients who need help managing their weight.

This guide explains exactly what changed, what's still available, and the practical steps you can take right now.

Editorial Independence Note: Telehealth Ally does not accept payment from providers for placement or ranking. This guide is based on independent research of DHCS policy documents and publicly available information. See our editorial policy for details.

Important: Medi-Cal managed care plans may have varying formularies. This guide reflects the statewide Medi-Cal policy as of April 2026 — always verify your specific plan's coverage before making treatment decisions.

What Changed on January 1, 2026

Effective January 1, 2026, the California Department of Health Care Services removed three GLP-1 medications from the Medi-Cal formulary when prescribed for weight loss:

Wegovy (semaglutide injection) — the branded anti-obesity version of semaglutide
Zepbound (tirzepatide injection) — the branded anti-obesity version of tirzepatide
Saxenda (liraglutide injection) — the branded anti-obesity version of liraglutide

The key distinction is indication. These medications are only dropped for the weight loss indication. The same active ingredients, marketed under different brand names for diabetes, remain on the formulary.

This means if your doctor prescribed Wegovy, Zepbound, or Saxenda specifically for weight management — and you don't have a concurrent type 2 diabetes diagnosis — Medi-Cal will no longer pay for your prescription. Patients who were already receiving these medications through Medi-Cal saw their coverage end when the new formulary took effect.

DHCS notified managed care plans in late 2025, but many patients report learning about the change only when their pharmacy rejected their refill. If this happened to you, you're not alone, and there are options available.

What Medi-Cal Still Covers

GLP-1 medications prescribed for type 2 diabetes remain fully covered under Medi-Cal. The following medications are still on the formulary:

Ozempic (semaglutide injection) — weekly injection for type 2 diabetes
Mounjaro (tirzepatide injection) — weekly injection for type 2 diabetes
Rybelsus (oral semaglutide) — daily pill for type 2 diabetes

This is an important distinction. Ozempic contains the exact same active ingredient as Wegovy (semaglutide). Mounjaro contains the exact same active ingredient as Zepbound (tirzepatide). The difference is the FDA-approved indication and the dose range.

If you have type 2 diabetes and obesity, you may still be able to access a GLP-1 through the diabetes indication. Many patients with obesity also have type 2 diabetes or prediabetes. Talk to your provider about whether a diabetes-indication GLP-1 is clinically appropriate for your situation.

Prior authorization is required for all GLP-1 medications on Medi-Cal. Your provider will need to submit documentation confirming the diabetes diagnosis and demonstrating medical necessity. Approval timelines vary by managed care plan but typically take 5-10 business days.

Medi-Cal GLP-1 Coverage Comparison Table

Medication	Active Ingredient	Weight Loss Indication	Diabetes Indication	Prior Auth Required	Monthly Cost on Medi-Cal
Wegovy	Semaglutide	Not covered	N/A (not approved for diabetes)	N/A	Not covered
Zepbound	Tirzepatide	Not covered	N/A (not approved for diabetes)	N/A	Not covered
Saxenda	Liraglutide	Not covered	N/A (not approved for diabetes)	N/A	Not covered
Ozempic	Semaglutide	Not covered	Covered	Yes	$0-$3 copay
Mounjaro	Tirzepatide	Not covered	Covered	Yes	$0-$3 copay
Rybelsus	Oral semaglutide	Not covered	Covered	Yes	$0-$3 copay

Note: Some Medi-Cal managed care plans charge $0 copay; others charge up to $3.80 per prescription for non-exempt adults. Children, pregnant individuals, and certain other categories pay no copay.

Why Did Medi-Cal Drop Weight Loss GLP-1 Coverage?

California's decision wasn't made lightly, and it reflects a financial reality facing Medicaid programs nationwide.

Budget Pressure

GLP-1 medications for weight loss are expensive — Wegovy carries a list price that, even after recent price cuts, runs hundreds of dollars per month per patient. With over 15 million Medi-Cal enrollees, pharmacy benefit costs for anti-obesity medications were projected to consume a rapidly growing share of Medi-Cal's pharmacy budget. DHCS estimated that covering weight loss GLP-1s for all eligible enrollees could add billions of dollars in annual spending.

Federal Medicaid Budget Negotiations

The decision came during a period of intense federal-level negotiations over Medicaid spending. States faced pressure to control costs as Congress debated potential changes to Medicaid funding formulas. California, which runs one of the largest Medicaid programs in the country, needed to demonstrate fiscal discipline.

Not a Clinical Judgment

It's worth noting that DHCS did not drop coverage because these medications don't work. The clinical evidence for GLP-1s in weight management is strong, and DHCS has acknowledged this. The decision was driven by budget constraints, not a change in the medical evidence.

Other States Watching

California isn't the only state considering this path. Several other state Medicaid programs have been evaluating their GLP-1 coverage policies, and California's decision may influence those deliberations. For a broader look at insurance coverage across programs, see our insurance coverage guide.

Your Options if You're Affected

If you were relying on Medi-Cal for weight loss GLP-1 coverage, here are the concrete alternatives available to you right now.

1. If You Have Type 2 Diabetes: Coverage May Continue

If you have a diagnosis of type 2 diabetes — even if your primary reason for taking a GLP-1 was weight loss — you may still qualify for Ozempic or Mounjaro through the diabetes indication. Ozempic and Mounjaro contain the same active ingredients as Wegovy and Zepbound, respectively, and produce weight loss as a documented benefit even when prescribed for diabetes.

Talk to your provider about whether this pathway is appropriate for you. Your provider will need to document the diabetes diagnosis and submit a prior authorization request. Be aware that the dosing ranges approved for diabetes may differ from those approved specifically for weight loss.

2. Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer patient assistance programs that may help bridge the gap:

NovoCare Patient Assistance Program — Novo Nordisk's program for Wegovy may offer reduced pricing or free medication for qualifying patients. Eligibility is based on income and insurance status. Visit NovoCare.com or call their helpline to check eligibility.
LillyDirect — Eli Lilly offers Zepbound through their direct-to-patient platform at $299 per month for self-pay patients. This doesn't require insurance and is available to anyone with a valid prescription.

These programs change frequently. Verify current pricing and eligibility directly with the manufacturer.

3. Telehealth Providers with Cash-Pay Options

Several telehealth platforms offer GLP-1 medications at competitive cash-pay prices, which may be more accessible than you'd expect. Pricing for compounded and branded options varies, but some platforms offer monthly plans starting under $200.

For a detailed comparison of what's available, see our online semaglutide provider comparison.

4. Orforglipron: The Affordable Oral Alternative

Orforglipron is a daily GLP-1 pill (not an injection) awaiting FDA approval expected around April 2026, with announced pricing of approximately $149 per month through LillyDirect. As an oral medication, it avoids the supply chain and cold storage issues that have historically affected injectable GLP-1s. While the weight loss results in clinical trials were somewhat lower than injectable semaglutide, many patients find the anticipated convenience and affordability compelling.

This is worth discussing with your provider, especially if injection cost was the primary barrier.

5. Generic Liraglutide (Teva's Saxenda Generic)

Teva's generic version of liraglutide (the same active ingredient as Saxenda) is available at approximately $230 per month — significantly less than branded Saxenda's former list price. While liraglutide produces less weight loss on average than semaglutide, it's a clinically proven option that may be more affordable for cash-pay patients.

See our generic liraglutide guide for a full breakdown.

6. CMS BALANCE Model: Potential Future Medicaid Coverage

The CMS BALANCE Model is a federal demonstration program designed to help state Medicaid programs cover anti-obesity medications. If California opts into BALANCE, it could restore some form of GLP-1 coverage for Medi-Cal enrollees — potentially with cost-sharing arrangements between the federal government, the state, and manufacturers.

As of April 2026, California has not officially opted into the BALANCE Model, but DHCS has indicated it is evaluating the program. This could be a path back to coverage, but it's not guaranteed and likely wouldn't take effect for months even if approved.

For more on the BALANCE Model, see our CMS BALANCE Model explainer.

7. File an Appeal

If your Medi-Cal coverage for a GLP-1 was denied, you have the right to appeal. Here's how:

Request the denial in writing. Your managed care plan must provide a written Notice of Action explaining the denial.
File a plan-level appeal within 60 days of the denial. Your provider can submit supporting documentation, including clinical notes, BMI history, and any comorbidities.
Request a State Fair Hearing if the plan-level appeal is denied. You can request this through the California Department of Social Services. There is no cost to file.
Request expedited review if your health is at immediate risk. Expedited appeals must be resolved within 72 hours.

Be realistic about appeal outcomes: if the medication was prescribed solely for weight loss and you don't have a diabetes diagnosis, the appeal will likely be denied because the formulary exclusion is a policy decision, not a clinical error. However, if you have comorbidities that weren't considered — such as undiagnosed prediabetes, cardiovascular risk factors, or sleep apnea — an appeal with additional clinical documentation may succeed.

For more guidance on navigating coverage denials, see our guide to insurance coverage loss.

How to Check Your Specific Medi-Cal Plan

Medi-Cal operates through managed care plans in most counties. While the statewide formulary sets the baseline, individual managed care plans may have additional restrictions or, in rare cases, supplemental coverage. Here's how to verify your specific situation:

Step 1: Identify Your Managed Care Plan

Your Medi-Cal card or Benefits Identification Card (BIC) lists your managed care plan. Common plans include:

Health Net
LA Care Health Plan
Molina Healthcare
Anthem Blue Cross
CalOptima (Orange County)
Partnership HealthPlan (Northern California)
Health Plan of San Joaquin
Central California Alliance for Health

Step 2: Call the Plan's Pharmacy Line

Call the member services number on your card and ask specifically: "Is [medication name] covered on my plan's formulary for [your indication]?" Have your diagnosis information ready.

Step 3: Ask About Prior Authorization

Even if a medication is listed on the formulary, it almost certainly requires prior authorization for GLP-1s. Ask what documentation your provider needs to submit and what the expected turnaround time is.

Step 4: Request a Formulary Exception

If the medication isn't on the formulary, you can request a formulary exception. This is different from an appeal — it's a request for the plan to cover a non-formulary drug based on medical necessity. Your provider will need to submit clinical justification explaining why the covered alternatives aren't appropriate for you.

Other States Watching California

California's decision to drop weight loss GLP-1 coverage has rippled across the country. Other large state Medicaid programs — including Texas, New York, Florida, and Illinois — are evaluating whether to follow suit. Some states that previously added GLP-1 weight loss coverage are now reconsidering as budget pressures mount.

The core tension is the same everywhere: GLP-1s are clinically effective but extraordinarily expensive at scale. A Medicaid program that covers weight loss GLP-1s for all eligible enrollees faces budget exposure that can run into billions annually.

For a comprehensive look at how different insurance programs — including employer plans, Medicare, and Medicaid — handle GLP-1 coverage, see our insurance coverage guide.

The Federal Angle: The CMS BALANCE Model

The federal government has acknowledged that Medicaid programs need help covering anti-obesity medications. The CMS BALANCE Model (Broad Access to Lifesaving Anti-Obesity Nutrition and Care for Everyone) is designed specifically to address this gap.

Under BALANCE, participating states would receive federal matching funds to help cover GLP-1 medications for Medicaid enrollees, combined with manufacturer discounts that reduce the per-patient cost to the state. The model also includes requirements for wraparound services — nutrition counseling, behavioral support, and monitoring — to maximize treatment effectiveness.

For Medi-Cal enrollees, the BALANCE Model represents the most likely pathway back to covered GLP-1 access for weight loss. But it requires California to apply, be accepted, and implement the program — a process that could take months.

We're tracking this closely. See our CMS BALANCE Model guide for the latest updates.

How to Save Money on GLP-1s Without Insurance Coverage

If you're paying out of pocket, every dollar matters. Here are additional strategies to reduce your costs:

Compare telehealth providers — pricing varies significantly across platforms. Some offer monthly plans under $200 for compounded semaglutide. See our money-saving guide.
Consider compounded options — compounded GLP-1 formulations may be available at lower prices, though the regulatory landscape is evolving. See our compounding alternatives guide.
Ask about pill formulations — oral GLP-1s like orforglipron and Rybelsus can be significantly cheaper than injectables.
Check manufacturer coupons — even without insurance, manufacturer programs sometimes offer introductory pricing or savings cards.

Frequently Asked Questions

Does Medi-Cal cover GLP-1 medications for weight loss in 2026?

No. As of January 1, 2026, Medi-Cal no longer covers Wegovy, Zepbound, or Saxenda when prescribed for weight loss. GLP-1 medications prescribed for type 2 diabetes (Ozempic, Mounjaro, Rybelsus) remain covered.

Does Medi-Cal cover Wegovy for weight loss?

No. Wegovy was removed from the Medi-Cal formulary for the weight loss indication effective January 1, 2026. If you have type 2 diabetes, your provider may be able to prescribe Ozempic (same active ingredient) under the diabetes indication.

Does Medi-Cal cover Ozempic for weight loss?

Ozempic is covered by Medi-Cal for type 2 diabetes, not for weight loss. While Ozempic frequently produces weight loss as a side benefit, it cannot be prescribed through Medi-Cal solely for weight management. Your provider would need to document a type 2 diabetes diagnosis.

Is Medi-Cal no longer covering GLP-1 medications?

Medi-Cal still covers GLP-1 medications prescribed for type 2 diabetes. What changed is that GLP-1s prescribed specifically for the weight loss indication — Wegovy, Zepbound, and Saxenda — are no longer covered. The distinction is based on the prescribing indication, not the drug class as a whole.

Can I appeal a Medi-Cal denial for a GLP-1 weight loss medication?

Yes, you have the right to appeal. File a plan-level appeal with your managed care plan within 60 days of the denial. If that's denied, you can request a State Fair Hearing at no cost. However, if the denial is based on the formulary exclusion (not a clinical decision), appeals are unlikely to succeed unless you have additional diagnoses that weren't originally considered.

What is the cheapest way to get a GLP-1 without Medi-Cal coverage?

Current options include orforglipron at approximately $149/month (oral pill), generic liraglutide at approximately $230/month, Zepbound through LillyDirect at $299/month, and various telehealth platforms offering compounded semaglutide at competitive prices. See our semaglutide provider comparison for current pricing.

Will Medi-Cal restore GLP-1 weight loss coverage?

It's possible but not guaranteed. If California opts into the federal CMS BALANCE Model, it could restore coverage with cost-sharing between the federal government, the state, and manufacturers. As of April 2026, California is evaluating the program but hasn't committed. We'll update this guide as the situation develops.

I was already taking Wegovy through Medi-Cal. What should I do?

Contact your provider immediately to discuss alternatives. Options include switching to Ozempic if you have a type 2 diabetes diagnosis, enrolling in a manufacturer savings program, exploring cash-pay telehealth options, or transitioning to a more affordable GLP-1 like orforglipron. Abruptly stopping a GLP-1 can lead to weight regain, so working with your provider on a transition plan is important.

This guide is for informational purposes only and does not constitute medical advice. Coverage policies change frequently — verify your specific Medi-Cal plan's formulary before making treatment decisions. If you're experiencing a medical emergency, call 911. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication.

Last verified: April 2026

Sarah Chen

Lead Health Editor

Sarah covers telehealth and digital health access. She has spent 8 years in health journalism, previously writing for health policy publications. She leads editorial at Telehealth Ally.

Medically Reviewed By

Dr. James Okafor, PharmD

Dr. Okafor is a licensed pharmacist who reviews medication guides and dosing content for clinical accuracy. He has 12 years of experience in clinical pharmacy.

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon Clinic vs Ro Health for GLP-1: retail giant pharmacy access vs dedicated weight loss program. Pricing, clinical depth, and medication access compared. April 2026.

Amazon One Medical vs PlushCare for GLP-1 Weight Loss: Which Is Better?

Amazon One Medical vs PlushCare head-to-head comparison for GLP-1 weight loss — pricing, medications, clinical approach, and whether a hybrid model beats pure telehealth.

Eden Health vs Ro for GLP-1: 2026 Comparison

Eden Health vs Ro compared side-by-side — flat-rate compounded pricing vs brand-name medications, and which GLP-1 provider fits your situation in 2026.

Medi-Cal GLP-1 Coverage in 2026: What's Covered, What's Not, and Your Options

Key Takeaways

Medi-Cal GLP-1 Coverage in 2026: What's Covered, What's Not, and Your Options

What Changed on January 1, 2026

What Medi-Cal Still Covers

Medi-Cal GLP-1 Coverage Comparison Table

Why Did Medi-Cal Drop Weight Loss GLP-1 Coverage?

Budget Pressure

Federal Medicaid Budget Negotiations

Not a Clinical Judgment

Other States Watching

Your Options if You're Affected

1. If You Have Type 2 Diabetes: Coverage May Continue

2. Manufacturer Savings Programs

3. Telehealth Providers with Cash-Pay Options

4. Orforglipron: The Affordable Oral Alternative

5. Generic Liraglutide (Teva's Saxenda Generic)

6. CMS BALANCE Model: Potential Future Medicaid Coverage

7. File an Appeal

How to Check Your Specific Medi-Cal Plan

Step 1: Identify Your Managed Care Plan

Step 2: Call the Plan's Pharmacy Line

Step 3: Ask About Prior Authorization

Step 4: Request a Formulary Exception

Other States Watching California

The Federal Angle: The CMS BALANCE Model

How to Save Money on GLP-1s Without Insurance Coverage

Frequently Asked Questions

Does Medi-Cal cover GLP-1 medications for weight loss in 2026?

Does Medi-Cal cover Wegovy for weight loss?

Does Medi-Cal cover Ozempic for weight loss?

Is Medi-Cal no longer covering GLP-1 medications?

Can I appeal a Medi-Cal denial for a GLP-1 weight loss medication?

What is the cheapest way to get a GLP-1 without Medi-Cal coverage?

Will Medi-Cal restore GLP-1 weight loss coverage?

I was already taking Wegovy through Medi-Cal. What should I do?

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon One Medical vs PlushCare for GLP-1 Weight Loss: Which Is Better?

Eden Health vs Ro for GLP-1: 2026 Comparison

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

CJC-1295 vs Ipamorelin: Complete Telehealth Comparison Guide 2026

CMS BALANCE Model Explained: Medicaid Obesity Care for 2026 and Beyond

Medicare GLP-1 Bridge Program: Implementation FAQ for Patients

Compounded GLP-1 Shutdown Timeline: From Shortage to Enforcement (2023–2026)

Is Compounded HRT Safe? What Patients Need to Know in 2026

Is Compounded Semaglutide Legal and Safe in 2026?

Compounded Tirzepatide 2026: What's Happening and What Patients Should Do

Contrave Guide 2026: How It Works, Weight Loss Results & How It Compares to GLP-1s

Does Insurance Cover GLP-1 Medications? Complete 2026 Guide

Does Insurance Cover Semaglutide? 2026 Coverage Guide